Literature DB >> 9668470

Different vaccine strategies used to protect against Theileria annulata.

N R Boulter1, C G Brown, E Kirvar, E Glass, J Campbell, S Morzaria, V Nene, A Musoke, C D'Oliveira, M J Gubbels, F Jongejan, F R Hall.   

Abstract

SPAG-1, a sporozoite surface antigen of T. annulata, has previously been shown to elicit partial protection when used, as an hepatitis B core antigen fusion, to immunize cattle. The objective of this study was to try and improve the protective capacity of this antigen by enlisting different vaccine strategies. Cattle were immunized with SPAG-1, as a fusion protein with a His6 tag, either incorporated into ISCOMs, with or without the merozoite antigens TAMS 1-1 and 1-2, or with RWL as adjuvant three times at monthly intervals. Another group of cattle were immunized with p67, the T. parva sporozoite antigen, in RWL to assess whether any cross-protection could be induced. The animals were then challenged with an estimated LD50 of T. annulata sporozoites, and their ability to resist the infection was investigated. Serum responses and T-cell proliferative responses were analyzed throughout the trial. Post-challenge analyses included lymph node biopsies and blood smears to check for the presence of parasites, routine hematological parameters, and observation for clinical manifestations of the disease. The results of this trial will be discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9668470     DOI: 10.1111/j.1749-6632.1998.tb11054.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

1.  Development of an indirect Tams1 enzyme-linked immunosorbent assay for diagnosis of Theileria annulata infection in cattle.

Authors:  M J Gubbels; C d'Oliveira; F Jongejan
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

2.  Validation of the indirect TaSP enzyme-linked immunosorbent assay for diagnosis of Theileria annulata infection in cattle.

Authors:  Dia Eldin A Salih; Jabbar S Ahmed; Mohammed A Bakheit; Elzein B Ali; Abdelrahim M El Hussein; Shawgi M Hassan; Omer E Shariff; M Fadl; Frans Jongejan
Journal:  Parasitol Res       Date:  2005-07-29       Impact factor: 2.289

3.  Molecular genetic characterization and subcellular localization of a putative Theileria annulata membrane protein.

Authors:  Ilka Schneider; Daniel Haller; Ulrike Seitzer; Doreen Beyer; Jabbar S Ahmed
Journal:  Parasitol Res       Date:  2004-10-14       Impact factor: 2.289

Review 4.  Molecular tools-advances, opportunities and prospects for the control of parasites of veterinary importance.

Authors:  Sachin Kumar; Snehil Gupta; Aquil Mohmad; Ashutosh Fular; B C Parthasarathi; Ashok Kumar Chaubey
Journal:  Int J Trop Insect Sci       Date:  2020-07-29       Impact factor: 0.774

Review 5.  Approaches to vaccination against Theileria parva and Theileria annulata.

Authors:  V Nene; W I Morrison
Journal:  Parasite Immunol       Date:  2016-12       Impact factor: 2.280

6.  Identification of candidate transmission-blocking antigen genes in Theileria annulata and related vector-borne apicomplexan parasites.

Authors:  Laetitia Lempereur; Stephen D Larcombe; Zeeshan Durrani; Tulin Karagenc; Huseyin Bilgin Bilgic; Serkan Bakirci; Selin Hacilarlioglu; Jane Kinnaird; Joanne Thompson; William Weir; Brian Shiels
Journal:  BMC Genomics       Date:  2017-06-05       Impact factor: 3.969

Review 7.  Immune Response to Tick-Borne Hemoparasites: Host Adaptive Immune Response Mechanisms as Potential Targets for Therapies and Vaccines.

Authors:  Alessandra Torina; Valeria Blanda; Sara Villari; Antonio Piazza; Francesco La Russa; Francesca Grippi; Marco Pio La Manna; Diana Di Liberto; José de la Fuente; Guido Sireci
Journal:  Int J Mol Sci       Date:  2020-11-20       Impact factor: 5.923

8.  Immuno-informatics Analysis to Identify Novel Vaccine Candidates and Design of a Multi-Epitope Based Vaccine Candidate Against Theileria parasites.

Authors:  Prajna Parimita Kar; Anand Srivastava
Journal:  Front Immunol       Date:  2018-10-15       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.